Cutera Company Overview: Devices, Revenue, Risk

Cutera at a Glance

Cutera is a medical-device manufacturer headquartered in Brisbane, California. Its portfolio focuses on energy-based aesthetic treatment systems sold into physician practices, dermatology offices, plastic-surgery groups, and med spas.

Cutera was founded in 1998 and has been building medical devices for 28 years. That operating history matters when evaluating an installed base. A platform with years in the field usually has a broader ecosystem of trained users, used equipment, service knowledge, and clinical familiarity than a brand-new product category.

Cutera's annual revenue is approximately $100M (est. 2025). That puts the company in a different position from the largest aesthetic-device manufacturers, which can spread service infrastructure and product-development costs across a wider base.

Cutera operates in 40+ countries under ticker CUTR. The public listing gives buyers access to filings and financial disclosures that private manufacturers do not provide. Read those filings before signing a multi-year service agreement. The device purchase is only part of the exposure.

The central fact is less comfortable. Cutera's stock fell from $45 to under $1 amid ongoing restructuring. A declining stock price does not tell you whether a particular system performs clinically. It does change the questions a practice should ask about service continuity, parts availability, warranty obligations, field support, and the value of a long contract.

What Cutera Is and What It Makes

Cutera is an aesthetic medical-device company. It designs and sells systems that use laser and radiofrequency technologies for visible skin concerns, acne treatment, body contouring, and vascular or pigment work.

For a physician, the practical question is whether a specific platform earns its footprint. A company profile tells you where the manufacturer is exposed. It does not tell you whether a particular handpiece, treatment protocol, consumable requirement, or patient demand fits your practice.

AviClear is the product most likely to come up in conversations about Cutera. The AviClear platform is built on a 1726nm laser, the first FDA-cleared energy device for acne. Acne is a large and durable patient-demand category, and a device built around that indication gives a practice a more distinct story than another broad skin-rejuvenation offering.

That distinction can help a practice market a treatment. It can also create concentration risk. A platform tied closely to one indication needs patient demand, staff confidence, and a treatment-price model that work in your market. The clinical category may be attractive while the economics remain thin.

truSculpt is Cutera’s body-contouring line. Body contouring has broad consumer awareness and heavy competition. Results, treatment comfort, treatment time, staffing needs, and local pricing shape whether a platform produces a useful return. Brand recognition helps. It does not carry the whole sales process.

Excel V+ sits in the vascular and pigment category, where treatment flexibility is often part of the appeal. Practices evaluating that platform should compare the clinical mix they already see with the procedures they expect to add. A system can be technically capable and still spend too much of its life unused.

Cutera’s device portfolio gives buyers exposure across categories that many aesthetic practices already understand. It also means the best purchasing decision may be platform-specific. A practice looking for acne treatment faces a different decision from one adding body contouring or vascular work.

Platform Portfolio by Category

AviClear is likely the clearest expression of Cutera’s product strategy. It offers a specific answer to a specific patient problem. The question is whether that specificity creates demand in your practice or leaves you with a costly system serving a narrow referral base.

truSculpt competes in a category full of claims, discounts, and consumer confusion. A buyer should build the purchase case from scheduled treatments, patient conversion, and local competition. Vendor projections can be useful inputs. They should not be the model.

Excel V+ deserves a more conventional clinical-capability review. Look at the procedures your clinicians perform now, the procedures they turn away, and the training needed to use the platform well. The vascular and pigment category gives useful context for the broader market around that decision.

Used-market activity can also tell you something about liquidity, though it does not establish clinical quality or future service access. Review the used Excel V+ market before treating a new-device quote as the only available path. The same approach applies to body contouring. The used truSculpt iD market is worth reviewing alongside the body contouring category before committing to a particular platform.

The Financial Picture: What Buyers Need to Know

Cutera’s restructuring is the part of this company overview that should change buyer behavior.

Cutera's stock fell from $45 to under $1 amid ongoing restructuring. That history does not mean every Cutera device should be avoided. It means a purchase cannot be evaluated as if the manufacturer carries ordinary financial risk.

Aesthetic-device buyers often focus on the visible pieces of the deal: purchase price, treatment revenue, training, financing, and launch support. Those matter. The risk becomes more acute after the initial sale, when a system needs parts, calibration, software support, a replacement handpiece, or a technician who can resolve an interruption quickly.

Ask who provides service in your territory. Get the answer in writing. Ask whether service is performed by Cutera employees, a third-party provider, or a mix. Ask what happens if the assigned provider changes. Ask which parts are covered, which parts are excluded, and what turnaround standard applies when a device is down.

Warranty language deserves the same scrutiny. A warranty only has value when its terms are clear and the responsible party can perform. Read the exclusions. Identify the consumables, accessories, and components that fall outside coverage. Confirm whether a transfer is possible if the device is sold or moved between entities.

The same caution applies to multi-year service contracts. A long agreement may offer predictable budgeting. It also ties your practice to a support arrangement that can become less attractive if the company’s circumstances change. Review Cutera’s SEC filings under ticker CUTR before signing. A finance director, counsel, or experienced equipment consultant can help interpret the contract and the company disclosures.

Resale assumptions belong in the file as well. A practice that buys a device with a weak resale market has less flexibility if patient demand misses the forecast, a clinician leaves, or the practice changes its treatment mix. Used-device pricing can move for many reasons, including new-product launches, service availability, installed-base demand, and buyer confidence in the manufacturer.

The service question is especially important for a platform you expect to use heavily. A system that generates revenue when it is available can create a mess when it is not. Patients need to be rescheduled. Staff lose time. Treatment plans become harder to manage. The lost revenue is only one part of the problem.

How to Evaluate a Cutera Purchase

Start with the treatment category, then work backward to the device.

For AviClear, estimate whether your practice can consistently reach the acne patients who are likely to consider an energy-based treatment. Review referral sources, existing acne volume, physician interest, consultation workflow, and the language your staff will use when discussing the treatment. A focused platform needs a focused demand engine.

For truSculpt, look past generic body-contouring demand. Identify the patient segment your practice reaches, the alternatives available nearby, and the price points your market supports. A body-contouring device can become a literal money pit when it relies on discounting to generate volume.

For Excel V+, begin with procedure mix. Vascular and pigment work can be a natural extension for some practices and an awkward side project for others. The platform needs an owner inside the practice: a clinician who wants to use it, a staff workflow that supports it, and a patient base that understands why the treatment belongs on the menu.

Then run the financial diligence in parallel. Do not wait until contract review to ask about service. The service structure may change the value of the offer more than a modest difference in purchase price.

A good vendor conversation should produce direct answers to a few practical questions:

• Who services the device locally, and how is that coverage documented?
• Which components, labor, travel, and replacement parts are covered under warranty?
• What support is available if a device issue interrupts scheduled treatments?
• Can the service agreement be transferred if the practice sells the system?
• What options exist if the manufacturer changes its service model?
• Which independent service providers can support the platform in your area?

The vendor may have strong answers. Get them in the contract, not in a slide deck or a follow-up email.

Where Cutera Wins, and Where Buyers Carry the Risk

Cutera wins when a practice wants a differentiated platform with a clear clinical use case. AviClear has an especially distinct position because The AviClear platform is built on a 1726nm laser, the first FDA-cleared energy device for acne. A strong clinical fit can outweigh a lot of background noise.

The buyer carries the risk when the purchase assumes stable service, stable resale value, or long-term manufacturer support without checking the underlying terms. Cutera's annual revenue is approximately $100M (est. 2025) and the company’s restructuring history should make those assumptions harder to accept without evidence.

Cutera’s technology can be well-regarded while its business faces pressure. Both facts belong in the decision. A practice that does the clinical work and the contract work has more room to benefit from the platform without pretending the company context does not exist.

The real question is whether Cutera can support your device for the full period your practice expects to own it.